Science Tranlational Medicine: To "escort" tumor immunotherapy, Chinese and American scientists released the latest cancer blocking combination therapy!

Today, tumor immunotherapy has entered a research outbreak.

However, it is worth noting that the current research shows that in patients with melanoma, non-small cell lung cancer and kidney cancer, less than 30% of the population can get good treatment with these inhibitors.

Recently, Chinese and American scientists from the Chinese Academy of Sciences, Sun Yat-sen University, Harvard Medical School, Tufts University, University of Maryland and other universities have jointly published a titled "Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in Science Tranlational Medicine.

DOI: 10.

Studies have pointed out that the PTEN gene is a tumor suppressor gene that has been widely studied at present, and it can directly participate in the regulation of the anti-tumor immune system

The researchers first developed a lipid-polymerization hybrid nanoparticle (NP) platform, and rigorously verified the lipid nanoparticles in PTEN mRNA encapsulation and maintenance of delivery stability.

The next step is the experimental phase.

The expression of PTEN under fluorescence immunoassay, from left to right are the control group without treatment, PTEN mRNA without encapsulation, lipid nanoparticles without PTEN mRNA, mPTEN@NPs

mPTEN@NPs therapy improves tumor cell death

After gratifying progress in in vitro experiments, the researchers conducted in vivo experiments in mice

Since previous studies have confirmed that the lack of PTEN can lead to adverse effects of anti-PD-1 targeted therapy, the researchers conducted experiments in melanoma mice with PTEN mutations to explore whether the repair of PTEN can promote anti-PD-1 Activation of the tumor immune system

After 3 rounds of treatment, the combination therapy of mPTEN@NPs+anti-PD-1 achieved better anti-tumor efficacy.

mPTEN@NPs+anti-PD-1 Combination Therapy Test Procedure and Results Analysis

The use of anti-CTLA-4 and anti-PD-1/PD-L1 as first-line therapies to treat non-small cell lung cancer and melanoma has been proven to be a very powerful cancer treatment method, even if the curative effect is limited, currently The medical industry will also use a combination of ICB therapy and traditional chemotherapy to enhance the immune response.

Original source:

Yao-Xin Lin, et al.